Ximelagatran: Direct Thrombin Inhibitor

References

• AlbersGWDienerHCFrisonLSPORTIF Executive Steering Committee, SPORTIF V InvestigatorsXimelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trialJAMA2005293690815701910
   PubMed Web of Science ®Google Scholar
• BungardTJGhaliWATeoKKWhy do patients with atrial fibrillation not receive warfarin?Arch Int Med200016041610632303
   PubMed Web of Science ®Google Scholar
• ColwellCWBerkowitzSDCompPCRandomised doubleblind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism after total knee replacement (Exult B study)Blood200310214a
   Web of Science ®Google Scholar
• DoraniHSchutzerKMSarichTCEffect of erythromycin on the pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran and its active form melagatran2004Proceedings American Society for Clinical Pharmacology and Therapeutics20–24 Jun 2004Miami Beach, FL, USA
   Google Scholar
• EikelboomJWHankeyGJThe beginning of the end of warfarin?Med J Aust20041805495115174982
   PubMed Web of Science ®Google Scholar
• EikelboomJWQuinlanDJDouketisJDExtended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomized trialsLancet200135891511454370
   PubMed Web of Science ®Google Scholar
• ElgMCarlssonSGustafssonDProlonged bleeding time induced by a direct thrombin inhibitor is reversed by recombinant factor VIIa in anaesthetized rats pre-treated with lipopolysaccharide [abstract]Blood20029844a
   Web of Science ®Google Scholar
• ErikssonBIAgnelliGCohenATDirect thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO III studyThromb Haemost2003a892889612574809
   PubMed Web of Science ®Google Scholar
• ErikssonBIAgnelliGCohenATThe direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS studyThromb Haemost2003b124906
   Web of Science ®Google Scholar
• ErikssonBIArfwidssonACFrisonLA dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgeryThromb Haemost200287231711858482
   PubMed Web of Science ®Google Scholar
• ErikssonBIBergqvistDKaleboPXimelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trialLancet20023601441712433510
   PubMed Web of Science ®Google Scholar
• ErikssonHErikssonUGFrisonLPharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVTThromb Haemost1999813586310102460
   PubMed Web of Science ®Google Scholar
• ErikssonHWahlanderKGustafssonDA randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE IThromb Haemost20031417
   Web of Science ®Google Scholar
• ErikssonUGBredbergUGislenKPharmacokinetics and pharmacodynamics of melagatran, a novel oral direct thrombin inhibitor, in young healthy male subjectsEur J Clin Pharmacol2003c591354312743672
   PubMed Web of Science ®Google Scholar
• ErikssonUGBredbergUHoffmanKJAbsorption, distribution, metabolism and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs and humansDrug Metab Dispos Mar2003d31294305
   PubMed Web of Science ®Google Scholar
• ErikssonUGJohanssonSAttmanPInfluence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatranClin Pharmacokinet2003427435312846595
   PubMed Web of Science ®Google Scholar
• ErikssonUGMandemaJWKarlssonMOPharmacokinetics of melagatran and the effect of ex vivo coagulation time orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysisClin Pharmacokinet2003e4268770112844328
   PubMed Web of Science ®Google Scholar
• ErikssonUGMandermaJWKarlssonMOPharmacokinetics of melagatran and the effect of ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysisClin Pharmocokinet2003f42687701
   Google Scholar
• FrancisCWBerkowitzSDCompPCEXULT A Study GroupComparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacementN Engl J Med200334917031214585938
   PubMed Web of Science ®Google Scholar
• FrancisCWGinsbergJSBerkowitzSDTHRIVE Treatment Study InvestigatorsEfficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: The THRIVE Treatment StudyBlood20031026a
   Web of Science ®Google Scholar
• GeertsWHPineoGFHeitJAPrevention of venous thromboembolism. The 7th ACCP Conference on Antithrombotic and Thrombolytic TherapyChest2004126338S400S15383478
   PubMed Web of Science ®Google Scholar
• GustafssonDAntonssonTBylundREffect of melagatran, a new low molecular weight thrombin inhibitor, on thrombin and fibrinolytic enzymesThromb Haemost199879110189459334
   PubMed Web of Science ®Google Scholar
• GustafssonDNyströmJECarlssonSThe direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effectsThromb Res20011011718111228340
   PubMed Web of Science ®Google Scholar
• HalperinJLExecutive Steering Committee, SPORTIF III and V Study InvestigatorsXimelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics – SPORTIF III and VAm Heart J2003146431812947359
   PubMed Web of Science ®Google Scholar
• HalperinJLExecutive Steering Committee, SPORTIF V InvestigatorsStroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation – SPORTIF VCirculation20031082723
   Web of Science ®Google Scholar
• JohanssonLCAnderssonMFagerGNo influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteersClin Pharmacokinet2003424758412739985
   PubMed Web of Science ®Google Scholar
• JohanssonSWahlanderKLarsonGPharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young menBlood Coagul Fibrinolysis2003146778414517494
   PubMed Web of Science ®Google Scholar
• KearonCGentMHirshJA comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolismN Engl J Med1999340901710089183
   PubMed Web of Science ®Google Scholar
• MattsonCBerntssonPMelagatran 2000. The active form of the oral direct thrombin inhibitor J376/95 enhances fibrinolysis via inhibition of thrombin-induced activation of pro-CPU [abstract]Blood200096989
   Web of Science ®Google Scholar
• NylanderSMattsonCThrombin-induced platelet activation and its inhibition by anticoagulants with different modes of actionBlood Coagul Fibrinolysis2003141596712632026
   PubMed Web of Science ®Google Scholar
• O'BrienCLGageBFCost and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillationJAMA200529369970615701911
   PubMed Web of Science ®Google Scholar
• OlssonSBExecutive Steering Committee on behalf of the SPORTIF III InvestigatorsStroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomised controlled trialLancet20033621691814643116
   PubMed Web of Science ®Google Scholar
• PetersenPGrindMAdlerJSPORTIF II InvestigatorsXimelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety studyJ Am Coll Cardiol20034114455112742279
   PubMed Web of Science ®Google Scholar
• SarichTCTengRErikssonUGNo influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatranClin Pharmacokinet2003424859212739986
   PubMed Web of Science ®Google Scholar
• SchulmanSWahlanderKLundstromTSecondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatranN Engl J Med200334917132114585939
   PubMed Web of Science ®Google Scholar
• SoslauGGoldenbergSJNavasE(Xi)melagatran inhibition of alpha-thrombin interaction between digoxin and ximelagatran, an oral direct thrombin inhibitor [abstract]Blood2002100255a
   Google Scholar
• WahlanderKLapidusLOlssonCTHRIVE IV: An openlabel, pilot study of the treatment of pulmonary embolism with the oral direct thrombin inhibitor ximelagatran [abstract]Blood200198268a
   Web of Science ®Google Scholar
• WallentinLWilcoxRGWeaverWDOral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomized controlled trialLancet20033627899713678873
   PubMed Web of Science ®Google Scholar